Foghorn Therapeutics (FHTX)
(Real Time Quote from BATS)
$5.38 USD
+0.14 (2.67%)
Updated Jun 21, 2024 11:28 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 1 - 20 ( 78 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Near/Long-Term Value Driven by FHD-286 in AML (2H24) And Diverse Pipeline Optionality
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Why Investors Should Take Note of the Renaissance Happening in Chromatin Biology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Showcases Robust Pipeline, Capabilities; Shares Appear Attractive
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
AACR?24 Event Highlights Formidable Novel Oncology Agents; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Cutting Through the Fog of Drug Development With Multiple Attacks on BAF: Reit Buy and $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Lily?s Selection of Foghorn?s FHD-909 Reinforces the Druggability of the Chromatin Remodeling System (CRS); Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
A Powerhouse of CRS Targeting Via Enzyme Inhibitors and Degraders: Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 AML Study Start in 3Q23, With Attractive Earlier-Stage Assets; Reit. Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 UM Update Refocuses Program Toward AML, Which We View As a Net Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 Data in mUM; The Juice Has to Be Worth the Squeeze
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R